NIPH Clinical Trials Search

Clinical Significance of Circulating Tumor Cells in Advanced Gastric Cancer

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Gastric Cancer
Date of first enrollment	04/09/2025
Target sample size	50
Countries of recruitment
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome	The Relationship of CLDN Expression Between Primary Tumors and Circulating Tumor Cells in the Blood
Secondary Outcome	The Relationship Between CLDN Expression in Circulating Tumor Cells and the Therapeutic Efficacy of Zolbetuximab-Based Chemotherapy

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	1. Histologically confirmed gastric adenocarcinoma diagnosed by pathological examination of endoscopic biopsy and/or surgical specimens. 2. Patients with stage IV advanced gastric cancer or recurrent gastric cancer. 3. HER2-negative status must be confirmed. 4. Patients aged 18 years or older at the time of consent, regardless of gender. 5. Patients receiving care either as inpatients or outpatients. 6. Patients diagnosed with gastric cancer and received medical care between April 1, 2025, and March 31, 2027.
Exclude criteria	1. Patients with synchronous multiple primary cancers. 2. Cases in which adenocarcinoma is not confirmed by pathological examination. 3. Patients who lack the capacity to provide informed consent. 4. Any other cases deemed inappropriate for study participation by the attending physician.